期刊
RHEUMATOLOGY
卷 59, 期 1, 页码 31-38出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kez113
关键词
rheumatoid arthritis; real-world data; registry; biomarkers; precision medicine
类别
资金
- NIHR Manchester BRC
- Arthritis Research UK [21754]
- MRC/Arthritis Research UK stratified medicine award [MR/K015346/1]
- MRC [MR/K015346/1] Funding Source: UKRI
Adding biomarker information to real world datasets (e.g. biomarker data collected into disease/drug registries) can enhance mechanistic understanding of intra-patient differences in disease trajectories and differences in important clinical outcomes. Biomarkers can detect pathologies present early in disease potentially paving the way for preventative intervention strategies, which may help patients to avoid disability, poor treatment outcome, disease sequelae and premature mortality. However, adding biomarker data to real world datasets comes with a number of important challenges including sample collection and storage, study design and data analysis and interpretation. In this narrative review we will consider the benefits and challenges of adding biomarker data to real world datasets and discuss how biomarker data have added to our understanding of complex diseases, focusing on rheumatoid arthritis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据